focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Here we go!
Once we close the gap up this morning from 89P, we should hopefully be back off to the races
Previous strong resistance at £1. Should be easily cleared today
It will be choppy today, orders being filled, shorts closed. I think we will finish on the high of the day
The Presentation at the US Cancer Conference is: Session Date and Time: Monday Apr 11, 2022 1:30 PM - 5:00 PM CT. So expect a further RNS on Monday or Tuesday, maybe with some more insight? Now is not the time to be selling!!
Yes Wiggly, that stuck out for me too. Let's see what tit-bits AS gives out today. Funding also looking good. Certainly no need to raise funds before release on data in summer 2022 which will help support share price. Also LFT aspect of business is alive and well. I personally expect sales in this financial year :)
Just load the telegram app and search Avacta.
https://ckgroup.co.uk/job/Lab-Manager/700643660915923/
Nice find from Basil Brush on Telegram.
Why bother unless the platform worked?
Yes, I had to place an NT trade. Maybe filling and order? Expect a rise from here going into the weekend.
Stoking interest for a US listing
How many clues do we need to show this tech is working :)
Just reinforces my belief that therapeutics is working and they want to focus on that.
Assay Development Scientist / Senior Assay Development Scientist, IVD
(dependent upon experience)
Avacta Life Sciences Ltd – Diagnostics
Location: Wetherby, Thorp Arch Estate
Reports to: Assay Development Project Leader (ADPL), IVD
Duration: Permanent
Hours: Full time (37.5 hrs/wk)
Travel: <10% of time
General Purpose and Scope
Avacta is at an early stage of commercialising its proprietary Affimer® technology which is a novel
engineered alternative to antibodies that has wide application in Life Sciences for in-vitro
diagnostics (IVD) and therapeutics. Key benefits of the Affimer reagents include specificity, stability,
reproducibility, and rapid development.
The Assay Development Scientist / Senior Assay Development Scientist (dependent upon
experience) will be involved in the successful delivery of IVD product development programmes,
within the framework of an ISO13485 certified Quality Management System and relevant UK & EU
IVD Directives and Regulations. The role includes planning, performance and reporting of work to
develop, optimise and validate a range of IVD assays, under the guidance of the ADPL.
Main Duties and Responsibilities
• Involvement in selected product development programmes through the various phases of
Design Control as defined by ISO13485, from the development of product design goals and
feasibility through to market launch.
• Responsibility for delivering projects, within the wider development programme, to timelines
and specifications, with associated deliverables.
• Working autonomously, design, develop and validate lateral flow assays for product
development programmes.
• Evaluate assay requirements, timelines, quality and accuracy of the experimental data
produced, ensuring that work is delivered in a timely manner.
• Comply with existing Standard Operating Procedures and validate new methods.
• Maintain accurate laboratory records.
• Attend and participate in meetings.
• Communicate experimental data verbally; contribute to scientific reports/presentations where
necessary.
• Participate in continued management, maintenance and improvement of the quality
management system, including but not limited to, commitment to the company Quality Policy,
generating and compiling NC/CAPAs, creating new, and updating existing documents and
processes through change management, participating in internal and certified body audits and
ensuring training is kept up to date
Regulatory Affairs Officer
This role will be responsible for carrying out a range of regulatory affairs duties to ensure compliance with ISO13485, CE marking requirements and other global regulatory requirements for IVDs within the framework of Avacta’s quality management system.
Quality Assurance Officer
The role will be responsible for supporting, managing and promoting ALS’s Quality Management System with the business ensuring compliance to ISO13485 and CE marking requirements and co-ordinating and supporting the manufacture of an IVD to ensure compliance with ISO13485.
The Assay Development Scientist / Senior Assay Development Scientist (dependent upon experience) will be involved in the successful delivery of IVD product development programmes, within the framework of an ISO13485 certified Quality Management System and relevant UK & EU IVD Directives and Regulations. The role includes planning, performance and reporting of work to develop, optimise and validate a range of IVD assays, under the guidance of the ADPL.
Description from website
Product Development Manager, IVD is a critical role to establish, manage, and successfully deliver IVD product development programmes, both in-house and partnered, within the framework of an ISO13485 certified Quality Management System and relevant UK & EU IVD Directives and Regulations. The role includes working across multidisciplinary commercial and technical teams and closely with the R&D/applications development team.
Not to over-egg the point but the Avacta website on Diagnostics https://avacta.com/diagnostics/ clearly makes reference to:
"Our diagnostics division is utilising our proprietary Affimer® platform to develop AffiDX®in vitro diagnostic (IVD) tests, starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test.
We have also established commercial relationships with IVD companies worldwide to improve the clinical utility of diagnostic testing solutions, by combining bespoke Affimer® reagents with leading diagnostic platform technologies."
Note use of "...starting with the AffiDX® SARS-CoV-2 Antigen Lateral Flow Test" (i.e they will be producing others) and that they "have established commercial relationships with IVD companies worldwide" - They are fully aware of the opportunity here that has come about purely as a result of Covid. So long as we do not deal with corrupt governments such as the UK, I am ok with that!!
In my view, it seems to me that the Gates Foundation, want access to the diagnostic ability because it gives them and their commercial partners (pharma) an in-road to large communities across the globe, where they can identify diseases/viruses and provide vaccines and/or other treatments, thus carrying on the gravy train for big pharma. If Avacta can be a cog in that machine to create shareholder value...I'm ok with that.
Morning all.
Wiggly, your post simply re-affirms that Avacta has by no means given up on LFT's. Not only have the invested heavily in this area and been ISO accredited, they're still recruiting as a previous poster pointed out earlier in the week https://avacta.com/careers/assay-development-scientist-senior-assay-development-scientist-ivd-dependent-upon-experience/ At some stage in the near future, I fully expect an update on commercial contracts for LFT's. The market for LFT's is vast and as well as covid there are many other viruses it can detect with the affimer platform. Time to accumulate. I continue to buy at these levels because I do not believe they will not be here for long.